Skin Cancers | Clinical

September 15, 2022

In the phase 3 CheckMate-76K study, adjuvant nivolumab administered to patients with stage IIB/C melanoma resulted in prolonged recurrence-free survival compared with placebo.

September 12, 2022

Neoadjuvant cemiplimab showed promising results in cutaneous squamous cell carcinoma with a near or complete disappearance of disease in almost 64% of patients set to undergo surgery.

September 05, 2022

A cohort of a clinical trial of the experimental agent STP705 successfully treated patients with cutaneous basal cell carcinomas, offering an alternative to surgery or other skin cancer treatment.

September 05, 2022

In patients with BRAF V600-mutated melanoma and central nervous system metastases, treatment with atezolizumab to vemurafenib plus cobimetinib achieved a good intracranial overall response rate. Responses were all achieved with the combination in patients with BRAF wild-type tumors.

September 03, 2022

Valencia D. Thomas, MD, MHCM, discusses the unmet needs which remain in the non-melanoma skin cancer space.

August 20, 2022

During a Targeted Oncology case-based event, Jason Luke, MD, and Laura K. Ferris, MD, PhD, discussed treatment for a patient with basal cell carcinoma.

July 26, 2022

Long-term follow-up in the COLUMBUS study shows continued survival improvement with encorafenib plus binimetinib and impressive disease control in patients with BRAF V600-mutant melanoma.

July 25, 2022

Treatment with ITI-3000 has begun in a first-in-human, phase 1 study of patients with Merkel cell carcinoma.

July 21, 2022

Valencia Thomas, MD, MHCM, MD Anderson Cancer Center, discusses the future for managing care in patients with non-melanoma skin cancers.

July 14, 2022

Niraj H. Mehta, MD, reviews the areas of the body where skin cancer can be hard to detect, what the skin cancer will look like on those parts of the body, risk factors for those receiving treatment, and follow-up for patients to catch recurrences.